GSK plc (GSK)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Vaccines/Respiratorysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-05. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 15/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: ?% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Hatteras Venture Partners Names Sir Andrew Witty as Chairman and Ned Sharpless, M.D., as Managing Director of Hatteras Discovery Innovation, Expanding Proven Investment Strategies
- GSK retains ‘buy’ rating at Jefferies as B7H3 cancer programme seen as underappreciated
- Berenberg Turns Bullish on GSK as its $750 Million Deal Adds to Pipeline Momentum
- GSK Adds Another Cancer Drug in a $750 Million Deal. Is its Oncology Bet Getting Bigger?
- GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity
- GSK Targets £40B Sales as Oncology Push and £1.9B Savings Plan Take Shape
- ALK appoints Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy
- GSK (LSE:GSK) Stock May Trade Below Fair Value Despite Fresh Cabenuva Trial News
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase II study (GeNeS1S trial). — Eur J Cancer 2026 Oct 16 PMID 42748587
- Presymptomatic plasma biomarkers in autosomal dominant Alzheimer's disease: sequence and timing. — J Neurol Neurosurg Psychiatry 2026 Aug 24 PMID 42637536
- International consensus on intestinal epithelial barrier assessment and therapeutic effects in inflammatory bowel diseases clinical trials. — Gut 2026 Jul 16 PMID 42463422
- Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer. — Curr Oncol 2026 Jun 1 PMID 42346230
- Developing low-carbon salbutamol MDI: assessment of relative bioavailability and pharmacodynamic relative potency of salbutamol MDI with propellant HFA-152a. — BMJ Open Respir Res 2026 Jun 17 PMID 42309649
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for GSK plc.
Full GSK Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.